- Home
- DHR
as 11-19-2025 3:36pm EST
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
| Founded: | 1969 | Country: | United States |
| Employees: | N/A | City: | WASHINGTON |
| Market Cap: | 148.8B | IPO Year: | N/A |
| Target Price: | $245.27 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 4.87 | EPS Growth: | -7.20 |
| 52 Week Low/High: | $171.00 - $258.23 | Next Earning Date: | 10-21-2025 |
| Revenue: | $24,268,000,000 | Revenue Growth: | 2.21% |
| Revenue Growth (this year): | 3.72% | Revenue Growth (next year): | 3.99% |
Stock Insider Trading Activity of Danaher Corporation (DHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ellis Brian W | DHR | Senior Vice President - GC | Nov 12 '25 | Sell | $219.22 | 21,776 | $4,773,863.14 | 14,553 | |
| RALES MITCHELL P | DHR | Chairman of Exec. Committee | Nov 12 '25 | Sell | $218.87 | 437,000 | $95,566,166.55 | 964,373 | |
| McGrew Matthew | DHR | EVP & Chief Financial Officer | Nov 11 '25 | Sell | $214.62 | 16,172 | $3,470,831.41 | 20,062 | |
| Couchara Georgeann | DHR | SVP, Human Resources | Nov 10 '25 | Sell | $210.38 | 5,174 | $1,088,703.65 | 2,625 | |
| RALES MITCHELL P | DHR | Chairman of Exec. Committee | Oct 31 '25 | Sell | $216.37 | 600,000 | $129,636,026.91 | 964,373 | |
| List Teri | DHR | N/A | Aug 22 '25 | Sell | $211.06 | 2,778 | $586,319.12 | 20,750.672 |
Latest Danaher Corporation News
DHR Breaking Stock News: Dive into DHR Ticker-Specific Updates for Smart Investing
Argus Research
a day ago
Technical Assessment: Bullish in the Intermediate-Term
GlobeNewswire
a day ago
Human Papilloma Virus (HPV) Test and Pap Smear/Test Market Research and Forecast Report 2025-2030, Competitive Analysis of Market leaders - Hologic, BD, Roche, QIAGEN, and Danaher
Insider Monkey
2 days ago
Jim Cramer Says BillionToOne Has a “Fantastic Story” Within the Diagnostics Space
Simply Wall St.
3 days ago
Shareholders 2.8% loss in Danaher (NYSE:DHR) partly attributable to the company's decline in earnings over past three years
Argus Research
5 days ago
Daily – Vickers Top Buyers & Sellers for 11/14/2025
Barchart
7 days ago
Danaher Stock Outlook: Is Wall Street Bullish or Bearish?
Zacks
7 days ago
SOLV vs. DHR: Which Stock Is the Better Value Option?
PR Newswire
7 days ago
IDBS announces i3 2026-An exclusive customer and partner event on data management innovation in BioPharma
Compare DHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DHR Danaher Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.